Stemmer Kerstin, Finan Brian, DiMarchi Richard D, Tschöp Matthias H, Müller Timo D
Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany; Helmholtz Diabetes Center & German Center for Diabetes Research (DZD), Helmholtz Zentrum München, Neuherberg, Germany; Department of Biology, University of Konstanz, Konstanz, Germany.
Novo Nordisk Research Center Indianapolis, Indianapolis, IN 46241, USA.
Adv Drug Deliv Rev. 2020;159:34-53. doi: 10.1016/j.addr.2020.05.008. Epub 2020 May 30.
Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.
甘油三酯和胆固醇代谢紊乱（血脂异常）是肥胖和2型糖尿病（T2D）患者发生心血管疾病的主要危险因素。一类新兴的胰高血糖素样肽-1（GLP-1）类似物以及下一代肽双激动剂，如GLP-1/胰高血糖素或GLP-1/胃抑肽，可为T2D患者提供有效的治疗选择。除了在葡萄糖和能量稳态中的作用外，GLP-1、胃抑肽和胰高血糖素还作为脂质代谢的调节剂。本综述总结了目前关于GLP-1、胰高血糖素和胃抑肽对脂质和脂蛋白代谢影响的知识，并阐述了GLP-1类似物和基于GLP-1的多激动剂作为糖尿病相关血脂异常附加治疗选择的新出现的治疗益处。
